Stocks
Nvidia Edges Out Eli Lilly as Top Bet for $10,000 Investment
Nvidia and Eli Lilly are both riding secular waves in the market, but which one is more promising for investors looking to make a $10,000 bet by 2026?
Eli Lilly's Mounjaro and Zepbound are leading the charge in the incretin revolution, with revenue up 47.7% year-over-year in Q2 2026 to $22.97 billion.
Nvidia, on the other hand, is powering the AI factory build-out, shipping Vera Rubin at full tilt, and reporting $96.22 billion in Q2 FY2027 revenue, a 105.8% increase from last year.
The main growth engine for Lilly is its GLP-1 franchise, while Nvidia's data center business is driving growth, with Data Center hitting $89.02 billion in Q2 FY2027.